Combination therapy with acitretin and glycyrrhizin in generalized pustular psoriasis with liver test abnormalities: A case series

Dermatol Ther. 2020 May;33(3):e13318. doi: 10.1111/dth.13318. Epub 2020 Mar 31.

Abstract

Liver test abnormalities (LTA) are a frequent extracutaneous manifestation in generalized pustular psoriasis (GPP). Due to possible hepatotoxicity of systemic monotherapy, it is challenging to simultaneously achieve clinical remission and LTA normalization. However, evidence for therapy is lacking. The aim of this study was to assess the effectiveness of combination therapy of acitretin and glycyrrhizin in nine GPP patients with LTA. During the acute phase of GPP, a combination of acitretin (0.5 mg/kg/d PO) and glycyrrhizin (80 mg/d intravenous) was initiated. After 2 weeks, all the patients promptly achieved at least 77% improvement in the severity score of GPP, as well as a significant reduction of liver enzymes. The patients were continuously treated with tapered doses of acitretin (20-30 mg/d PO) and glycyrrhizin (150 mg/d PO), and presented stable conditions during the 12-month follow-up. In conclusion, we consider that the combination of acitretin plus glycyrrhizin is an effective and safe therapy in GPP patients with LTA.

Keywords: acitretin; generalized pustular psoriasis; glycyrrhizin; liver test abnormalities.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acitretin*
  • Glycyrrhizic Acid
  • Humans
  • Keratolytic Agents
  • Liver
  • Psoriasis* / diagnosis
  • Psoriasis* / drug therapy

Substances

  • Keratolytic Agents
  • Glycyrrhizic Acid
  • Acitretin